Categories 2022 Internal Dealing Alessandro Maiello – Internal Dealing Post author By Paolo Cimmino Post date 17 October 2022 Alessandro Maiello – Internal Dealing ← Board of Directors to approve Q3 2022 revenues and key KPIs (unaudited) → Farmacosmo Partecipa, Come Unica Azienda Italiana, All’Evento Dell’European Association Of E-Pharmacies
Farmacosmo InvestorsFarmacosmo Investors